Pharma Research and Early Development (pRED)
Grenzacherstrasse 124
CH-4070 Basel
Switzerland

 

roche.com

Project leader

 
Mr. Martin Graf
IMI StemBANCC Coordinator
Head of Stem Cell Platform
Discovery Technologies
E-Mail  

Project staff

 
Dr. Nicole Clemann
WP10 co-leader
Non Clinical Safety
E-Mail  

 

 
Dr. Mark Burcin
WP3 co-leader
Lab Leader, Stem Cell Platform
Discovery Technologies
E-Mail  

 

 
Mr. Klaus Christensen
WP03
Lab Leader, Stem Cell Platform
Discovery Technologies
E-Mail  

 

 
Dr. Ravi Jagasia
WP08 - CNS
Lab Leader, Neuroscience Discovery
E-Mail  

 

 
Dr. Hansruedi Loetscher
WP08 - CNS
Head Molecular Neuroscience
Neuroscience Discovery
E-Mail  

 

   
Dr. Anna-Lisa Gündner
WP08 - CNS
Post Doc, Neuroscience Discovery
E-Mail  

 

   
Dr. Roberto Iacone
WP09 - Diabetes
Group Leader, Cardiovascular & Metabolic Diseases
E-Mail  

 

 
Dr. Osele Ciampi

WP09 WP10 

Post Doc, Cardiovascular & Metabolic Diseases
E-Mail  

Institute presentation

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.